MOLECULAR PARTNERS ADS/1
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more
MOLECULAR PARTNERS ADS/1 (6ML0) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, MOLECULAR PARTNERS ADS/1 (6ML0) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
MOLECULAR PARTNERS ADS/1 - Net Assets Trend (None–None)
This chart illustrates how MOLECULAR PARTNERS ADS/1's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MOLECULAR PARTNERS ADS/1 (None–None)
The table below shows the annual net assets of MOLECULAR PARTNERS ADS/1 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to MOLECULAR PARTNERS ADS/1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
MOLECULAR PARTNERS ADS/1 Competitors by Market Cap
The table below lists competitors of MOLECULAR PARTNERS ADS/1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Alterity Therapeutics Ltd
NASDAQ:ATHE
|
$67.51 Million |
|
TBS Energi Utama Tbk PT
JK:TOBA
|
$67.53 Million |
|
ReproCELL Incorporated
F:6RC
|
$67.55 Million |
|
SAI SILKS (KALAMANDIR) LIMITED
NSE:KALAMANDIR
|
$67.55 Million |
|
Atinum Investment Co. Ltd
KQ:021080
|
$67.49 Million |
|
Century Enka Limited
NSE:CENTENKA
|
$67.49 Million |
|
Carlo Gavazzi Holding AG
SW:GAV
|
$67.49 Million |
|
SaltX Technology Holding AB
ST:SALT-B
|
$67.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MOLECULAR PARTNERS ADS/1's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares MOLECULAR PARTNERS ADS/1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently MOLECULAR PARTNERS ADS/1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares MOLECULAR PARTNERS ADS/1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,345,847,517
- Average return on equity (ROE) among peers: -601.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MOLECULAR PARTNERS ADS/1 (6ML0) | €- | N/A | N/A | $67.50 Million |
| 09R (09R) | $5.86 Million | -145.33% | 0.68x | $12.96 Million |
| IDORSIA AG (19T) | $104.20 Million | -608.99% | 13.23x | $582.75 Million |
| 1S90 (1S90) | $10.78 Million | -2319.92% | 31.35x | $54.21 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.28 Million |
| 25K0 (25K0) | $-79.67 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $508.00K | -2193.11% | 12.24x | $9.80 Million |
| Intervacc AB (publ) (2E9) | $308.25 Million | -9.53% | 0.07x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $3.03 Million | -558.03% | 2.82x | $9.20 Million |
| GNI Group Ltd (3G6) | $13.10 Billion | 1.39% | 0.57x | $772.60 Million |